Lion Biotechnologies (LBIO) 7.92 $LBIO
Lion Biotechnologies' Annual Meeting Rescheduled
Marketwired - Wed Jun 08, 3:05PM CDT
NEW YORK, NY--(Marketwired - June 08, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that its Board of Directors will reschedule the company's 2016 Annual Meeting of Stockholders, which was originally scheduled for Friday, June 10, 2016.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Announces Closing of $100 Million Private Financing
Marketwire Canada - Wed Jun 08, 7:01AM CDT
NEW YORK, NY--(Marketwired - June 08, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO) announced today the closing of its previously announced private financing with institutional and other accredited investors. Lion Biotechnologies received gross proceeds of $100 million, before paying the placement agents' fees and estimated offering expenses payable by the Company. At the closing, the Company issued 9,684,000 shares of common stock and 11,368,633 shares of its new non-voting Series B Preferred Stock.
LBIO: 7.92 (-0.09)
Lion Biotechnologies to Present at the Jefferies 2016 Healthcare Conference
Marketwire Canada - Fri Jun 03, 10:15AM CDT
NEW YORK, NY--(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced today that Lion management will present a company overview at the upcoming Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2:30pm E.T in New York, NY.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Appoints Maria Fardis, Ph.D., as CEO
Marketwired - Fri Jun 03, 8:34AM CDT
NEW YORK, NY--(Marketwired - June 03, 2016) -
LBIO: 7.92 (-0.09)
Lion Biotechnologies Raises Approximately $100 Million in Private Placement
Marketwire Canada - Fri Jun 03, 8:31AM CDT
NEW YORK, NY--(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO) today announced that it has entered into a securities purchase agreement with institutional and other accredited investors under which the investors have agreed to purchase a total of 9,684,000 shares of common stock and approximately 11,368,500 shares of newly authorized Series B Preferred Stock in a private placement for aggregate gross proceeds of approximately $100.0 million. The purchase price will be $4.75 for each share of common stock and $4.75 for each share of Series B Preferred Stock. The offering is expected to close on or about June 7, 2016, subject to customary closing conditions.
LBIO: 7.92 (-0.09)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Lion Biotechnologies, Inc. - LBIO
PR Newswire - Mon May 23, 3:23PM CDT
Levi & Korsinsky announces it has commenced an investigation of Lion Biotechnologies, Inc. (NASDAQ: LBIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
LBIO: 7.92 (-0.09)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Lion Biotechnologies, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 23, 6:42AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Lion Biotechnologies, Inc. (NASDAQ: LBIO).
LBIO: 7.92 (-0.09)
Lion Biotechnologies reports 1Q loss
Automated Insights - Mon May 09, 7:10AM CDT
NEW YORK (AP) _ Lion Biotechnologies Inc. (LBIO) on Monday reported a loss of $6.9 million in its first quarter.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Announces First Quarter 2016 Financial Results
Marketwired - Mon May 09, 7:01AM CDT
NEW YORK, NY --(Marketwired - May 09, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today reported its first quarter 2016 financial results and provided a corporate update.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Manufacturing Capabilities and Research Programs Unaffected by Review of National Cancer Institute's Manufacturing Facilities
Marketwired - Sun Apr 17, 10:00AM CDT
Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced that it has learned that the cell therapy manufacturing facilities at the National Cancer Institute (NCI) are undergoing a voluntary internal review by the National Institutes of Health (NIH) in connection with the NIH's review of all NCI facilities involving sterile material. TIL studies conducted by the NCI are among those suspended until the review is complete.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
Marketwired - Mon Mar 28, 7:01AM CDT
Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Michael T. Lotze, MD, as chief scientific officer (CSO) and vice president of research and development, effective immediately.
LBIO: 7.92 (-0.09)
Lion Biotechnologies' Annual Meeting Rescheduled
Marketwired - Wed Jun 08, 3:05PM CDT
NEW YORK, NY--(Marketwired - June 08, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that its Board of Directors will reschedule the company's 2016 Annual Meeting of Stockholders, which was originally scheduled for Friday, June 10, 2016.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Announces Closing of $100 Million Private Financing
Marketwire Canada - Wed Jun 08, 7:01AM CDT
NEW YORK, NY--(Marketwired - June 08, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO) announced today the closing of its previously announced private financing with institutional and other accredited investors. Lion Biotechnologies received gross proceeds of $100 million, before paying the placement agents' fees and estimated offering expenses payable by the Company. At the closing, the Company issued 9,684,000 shares of common stock and 11,368,633 shares of its new non-voting Series B Preferred Stock.
LBIO: 7.92 (-0.09)
Lion Biotechnologies to Present at the Jefferies 2016 Healthcare Conference
Marketwire Canada - Fri Jun 03, 10:15AM CDT
NEW YORK, NY--(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced today that Lion management will present a company overview at the upcoming Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2:30pm E.T in New York, NY.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Appoints Maria Fardis, Ph.D., as CEO
Marketwired - Fri Jun 03, 8:34AM CDT
NEW YORK, NY--(Marketwired - June 03, 2016) -
LBIO: 7.92 (-0.09)
Lion Biotechnologies Raises Approximately $100 Million in Private Placement
Marketwire Canada - Fri Jun 03, 8:31AM CDT
NEW YORK, NY--(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO) today announced that it has entered into a securities purchase agreement with institutional and other accredited investors under which the investors have agreed to purchase a total of 9,684,000 shares of common stock and approximately 11,368,500 shares of newly authorized Series B Preferred Stock in a private placement for aggregate gross proceeds of approximately $100.0 million. The purchase price will be $4.75 for each share of common stock and $4.75 for each share of Series B Preferred Stock. The offering is expected to close on or about June 7, 2016, subject to customary closing conditions.
LBIO: 7.92 (-0.09)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Lion Biotechnologies, Inc. - LBIO
PR Newswire - Mon May 23, 3:23PM CDT
Levi & Korsinsky announces it has commenced an investigation of Lion Biotechnologies, Inc. (NASDAQ: LBIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
LBIO: 7.92 (-0.09)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Lion Biotechnologies, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 23, 6:42AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Lion Biotechnologies, Inc. (NASDAQ: LBIO).
LBIO: 7.92 (-0.09)
Lion Biotechnologies reports 1Q loss
Automated Insights - Mon May 09, 7:10AM CDT
NEW YORK (AP) _ Lion Biotechnologies Inc. (LBIO) on Monday reported a loss of $6.9 million in its first quarter.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Announces First Quarter 2016 Financial Results
Marketwired - Mon May 09, 7:01AM CDT
NEW YORK, NY --(Marketwired - May 09, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today reported its first quarter 2016 financial results and provided a corporate update.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Manufacturing Capabilities and Research Programs Unaffected by Review of National Cancer Institute's Manufacturing Facilities
Marketwired - Sun Apr 17, 10:00AM CDT
Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced that it has learned that the cell therapy manufacturing facilities at the National Cancer Institute (NCI) are undergoing a voluntary internal review by the National Institutes of Health (NIH) in connection with the NIH's review of all NCI facilities involving sterile material. TIL studies conducted by the NCI are among those suspended until the review is complete.
LBIO: 7.92 (-0.09)
Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
Marketwired - Mon Mar 28, 7:01AM CDT
Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Michael T. Lotze, MD, as chief scientific officer (CSO) and vice president of research and development, effective immediately.
LBIO: 7.92 (-0.09)
